We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
-10.17%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$4.15B
AUM Growth
-$1.56B
Cap. Flow
-$673M
Cap. Flow %
-16.21%
Top 10 Hldgs %
47.21%
Holding
133
New
21
Increased
21
Reduced
31
Closed
23

Top Buys

Rank Stock Value
1
IOVA icon
Iovance Biotherapeutics
IOVA
+$71.4M
2
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$45.8M
3
IMTX icon
Immatics
IMTX
+$39.5M
4
CTNM
Contineum Therapeutics
CTNM
+$25.2M
5
ACRV icon
Acrivon Therapeutics
ACRV
+$19M

Top Sells

Rank Stock Value
1
INBX
Inhibrx, Inc. Common Stock
INBX
+$149M
2
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
+$146M
3
MDT icon
Medtronic
MDT
+$77M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$68.1M
5
AXSM icon
Axsome Therapeutics
AXSM
+$47.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.74%
2 Miscellaneous 0.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTGX icon
26
Protagonist Therapeutics
PTGX
$9.28B
$44M 1.06%
1,268,735
+274,412
+28% +$8.04M
SLDB icon
27
Solid Biosciences
SLDB
$897M
$39.2M 0.94%
6,906,646
– –
CELC icon
28
Celcuity
CELC
$4.05B
$38.7M 0.93%
2,362,279
– –
MDT icon
29
Medtronic
MDT
$120B
$38.6M 0.93%
490,665
-938,898
-66% -$77M
VKTX icon
30
Viking Therapeutics
VKTX
$3.49B
$38.2M 0.92%
721,377
-272,721
-27% -$17.9M
APLT
31
DELISTED
Applied Therapeutics
APLT
$37.4M 0.9%
8,005,000
– –
AXSM icon
32
Axsome Therapeutics
AXSM
$10.7B
$37M 0.89%
459,111
-646,230
-58% -$47.8M
CNTA
33
DELISTED
Centessa Pharmaceuticals
CNTA
$35.5M 0.86%
3,933,307
+850,000
+28% +$8.06M
TARS icon
34
Tarsus Pharmaceuticals
TARS
$3.66B
$35.2M 0.85%
1,296,416
– –
VRNA
35
DELISTED
Verona Pharma
VRNA
$35.2M 0.85%
2,433,725
-1,327,851
-35% -$19.4M
AKRO
36
DELISTED
Akero Therapeutics
AKRO
$35.2M 0.85%
1,499,897
+112,426
+8% +$2.4M
EWTX icon
37
Edgewise Therapeutics
EWTX
$4.74B
$33.4M 0.81%
1,856,417
-463,229
-20% -$8.08M
ACRV icon
38
Acrivon Therapeutics
ACRV
$78.4M
$31.1M 0.75%
5,360,858
+2,353,000
+78% +$19M
PRAX icon
39
Praxis Precision Medicines
PRAX
$8.74B
$31M 0.75%
750,230
-71,359
-9% -$3.37M
ADMA icon
40
ADMA Biologics
ADMA
$1.93B
$31M 0.75%
2,771,000
-3,662,369
-57% -$30.7M
BBIO icon
41
BridgeBio Pharma
BBIO
$13.4B
$30.8M 0.74%
1,215,346
-196,687
-14% -$5.38M
ALDX icon
42
Aldeyra Therapeutics
ALDX
$82.6M
$30.7M 0.74%
9,275,851
+682,265
+8% +$2.67M
NAUT icon
43
Nautilus Biotechnolgy
NAUT
$113M
$29.5M 0.71%
12,594,211
– –
CTNM
44
Contineum Therapeutics
CTNM
$520M
$27.6M 0.66%
+1,566,668
New +$25.2M
ISRG icon
45
Intuitive Surgical
ISRG
$133B
$27.5M 0.66%
61,800
-40,000
-39% -$15.9M
ARVN icon
46
Arvinas
ARVN
$540M
$27.4M 0.66%
1,027,749
-208,854
-17% -$6.65M
RCKT icon
47
Rocket Pharmaceuticals
RCKT
$374M
$26.8M 0.65%
1,246,597
-554,471
-31% -$12.7M
IRON icon
48
Disc Medicine
IRON
$2.58B
$24.9M 0.6%
553,437
-386,429
-41% -$13.1M
LIVN icon
49
LivaNova
LIVN
$4.38B
$24.3M 0.59%
444,000
+145,000
+48% +$8.26M
CGON icon
50
CG Oncology
CGON
$6.43B
$23.2M 0.56%
733,695
-570,410
-44% -$19.8M
1
2
3 4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q2 2024 Portfolio in Review

As of Q2 2024, Perceptive Advisors held 133 positions worth $4.15B, down 27% from $5.72B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Perceptive Advisors withdrew a net $673M in Q2 2024, closing 23 positions and reducing 31 holdings. Its most notable exit was Inhibrx, Inc. Common Stock, an estimated $149M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Miscellaneous.

Against the trend, Perceptive Advisors opened a new position in Contineum Therapeutics worth $27.6M.

  • Perceptive Advisors's largest Q2 2024 buy was Contineum Therapeutics: 1,566,668 shares worth $27.6M.
  • Perceptive Advisors added most to Iovance Biotherapeutics in Q2 2024, an estimated $71.4M increase.
  • Perceptive Advisors's biggest Q2 2024 reduction was Medtronic, cutting an estimated $77M.
  • Perceptive Advisors fully exited Inhibrx, Inc. Common Stock in Q2 2024, selling an estimated $149M.
  • Perceptive Advisors's ten largest holdings make up 47% of its $4.15B portfolio in Q2 2024.
  • Perceptive Advisors opened 21 new positions and closed 23 in Q2 2024.
  • Perceptive Advisors's portfolio value fell 27% quarter-over-quarter to $4.15B.

Based on Perceptive Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.